Pricing Log in Create free account

Bolt Biotherapeutics, Inc. (BOLT) vs Karyopharm Therapeutics Inc. (KPTI)

Bolt Biotherapeutics, Inc. and Karyopharm Therapeutics Inc. are both Biotechnology companies. Bolt Biotherapeutics, Inc. and Karyopharm Therapeutics Inc. are of similar size ($8.2M and $8.0M). Bolt Biotherapeutics, Inc. grew revenue faster over the last twelve months: 12.8% against 6.81%. Karyopharm Therapeutics Inc. has the higher net margin (−153.3% vs −611.5%) and the higher return on invested capital (0.00% vs −143.8%). Across the 17 metrics below, Karyopharm Therapeutics Inc. leads on 9 and Bolt Biotherapeutics, Inc. on 8.

Valuation

Metric BOLT KPTI Biotechnology median
P/E n/m n/m 8.50
P/S 1.46 0.08 9.71
P/B 0.54 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 1.62 1.34 9.21
Earnings yield (404.93%) (3,634.56%) (33.15%)
Free cash flow yield (448.90%) (580.28%) (25.50%)

Profitability

Metric BOLT KPTI Biotechnology median
Gross margin 100.00% 95.89% 65.16%
Operating margin (654.53%) (56.17%) 0.00%
Net margin (611.47%) (153.28%) 0.00%
Free cash flow margin (655.72%) (44.57%) 0.00%
Return on equity (111.65%) 78.98% (56.36%)
Return on assets (49.62%) (207.90%) (48.04%)
Return on invested capital (143.75%) 0.00% 0.00%

Growth

Metric BOLT KPTI Biotechnology median
Revenue growth (TTM) 12.79% 6.81% 6.02%
EPS growth (last fiscal year) 45.91% (98.37%) 30.26%
Revenue growth, 5-year CAGR 101.61% 6.21% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BOLT KPTI Biotechnology median
Debt to equity 1.47 (0.76) 0.00
Current ratio 2.61 0.79 4.72
Net debt to EBITDA 0.21 (2.03) 0.96

Dividend

Metric BOLT KPTI Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric BOLT KPTI Biotechnology median
Market cap 8.17m 7.95m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack